批评者质疑印度新药批准规则, Critics question India's new drug approval rules, citing fairness concerns.

专家质疑印度新药批准规则, Experts question India's new drug approval rules, which allow waivers for drugs approved in major markets. 然而,出现了不一致的情况,特别是对于在这些外国市场未获批准的本国开发药物. However, inconsistencies have emerged, particularly for indigenously developed medicines not approved in those foreign markets. 批评者认为这种缺乏清晰性和公平性的做法可能会阻碍原创研究, 而有利于模仿, Critics argue this lack of clarity and fairness may discourage original research and favor imitation, threatening India's goal of becoming a global pharmaceutical innovation hub.